PWS
JAZZ icon

Paragon Wealth Strategies’s Jazz Pharmaceuticals JAZZ Stock Holding History

Paragon Wealth Strategies’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-120
Closed -$21K – 166
2021
Q2 		$21K Buy
+120
New +$20.8K 0.01% 128

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Paragon Wealth Strategies's JAZZ Position: Q3 2021 in Review

Paragon Wealth Strategies sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 120 shares — an estimated $21K sold.

Paragon Wealth Strategies first reported a position in JAZZ in Q2 2021 and held it in 1 quarter. The position peaked at $21K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

  • Paragon Wealth Strategies reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Paragon Wealth Strategies sold 120 Jazz Pharmaceuticals shares in Q3 2021, an estimated $21K.
  • Paragon Wealth Strategies first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Paragon Wealth Strategies's Jazz Pharmaceuticals position peaked at $21K in Q2 2021.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Paragon Wealth Strategies's 13F filing for Q3 2021, filed 29 Oct 2021.